-
Sector Analysis
Bladder Cancer Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. This report includes an assessment of the disease epidemiology and 10-year patient-based...
-
Thematic Analysis
South Korea Drug Development Trends - Strategic Intelligence
South Korea has become a significant player in the global pharmaceutical industry and drug development space, fueled by its advanced healthcare system, growing pharmaceutical sector, strong research infrastructure, and government-backed initiatives to support innovation. The country has been increasingly focusing on innovation and cutting-edge technologies, such as CGTs, as well as development of advanced therapies such as ADCs, mRNA-based treatments, and CAR-T therapies. As a result, South Korea is establishing itself as a growing hub for clinical trials and drug...
-
Sector Analysis
Major Depressive Disorder in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2029
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Major Depressive Disorder market through 2029.
-
Sector Analysis
Major Depressive Disorder in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2029
This report covers the 8 major markets and provides an Excel-based forecast model for the Major Depressive Disorder market through 2029.
-
Sector Analysis
Myelodysplastic Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. - GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. - MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. - The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase...
-
Sector Analysis
Polycystic Kidney Disease (PKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics. - GlobalData epidemiologists estimate that there were 1.19 million diagnosed prevalent cases of Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PKD & ADPKD) infection in 2024, which is expected to increase slightly to 1,23 million diagnosed prevalent cases by 2029. - Currently, there is only one approved innovator therapy available...
-
Product Insights
Acute Lymphocytic Leukemia (ALL) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Global Clinical Trials Review, 2025" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Diffuse Cutaneous Systemic Sclerosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diffuse Cutaneous Systemic Sclerosis - Global Clinical Trials Review, 2025" provides an overview of Diffuse Cutaneous Systemic Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Cutaneous Systemic Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Fragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Fragile X Syndrome - Global Clinical Trials Review, 2025" provides an overview of Fragile X Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Fragile X Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diabetic Macular Edema - Global Clinical Trials Review, 2025" provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.